ProMIS Neurosciences Announces First Quarter 2020 Results

    NEXT STORY
    Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
    PREV STORY
    PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Relievant Announces Level I INTRACEPT Study Enrollment Stopped Early for Superiority

    Intracept® Procedure Demonstrates Highly Significant Treatment Effect vs. Non-Surgical Management MINNEAPOLIS, Jan. 30, 2019 ...

    author_avatar
    NASDAQ Market News

    Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director

    author_avatar
    NASDAQ Market News

    Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

    Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children ...

    author_avatar
    NASDAQ Market News